Impact of a Value-Based Formulary in Three Chronic Disease Cohorts

摘要

OBJECTIVES: Value-based insurance design has been suggested as an effective approach to ensure access to high-value medications in health insurance markets. Premera Blue Cross, a large regional health plan, implemented a value-based formulary (VBF) for pharmaceuticals in 2010 that explicitly used cost-effectiveness analysis to inform medication co-payments. This study assesses the impact of a VBF on adherence and patient and health plan expenditures on 3 chronic disease states: diabetes, hypertension, and hyperlipidemia.